default author photo

Ashwath Gurumurthi

University of Texas at Houston

Houston, TX 77030

United States

SCHOLARLY PAPERS

1

DOWNLOADS

75

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety and Activity of Lenalidomide in Combination with Obinutuzumab in Patients with Relapsed Indolent Non-Hodgkin Lymphoma: A Single Group, Open-Label, Phase 1/2 Trial

Number of pages: 42 Posted: 08 Apr 2024
University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 75 (837,727)

Abstract:

Loading...

Follicular Lymphoma, B-Cell Lymphoma, Lenalidomide, Therapeutic Use, Obinutuzumab, Antineoplastic Agents, Immunological